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Facts and Demographics
Acute Myeloid Leukemia, or AML, also known as acute 
myelogenous leukemia and acute nonlympocytic leukemia (ANLL), 
is a disease that is estimated to affect 21,380 people in the U.S., 
killing 10,590 this year alone according to the National Institute of 
Cancer (NIC, 2017).
AML is a disease of the myeloid cells in the bone marrow. These 
cells proliferate uncontrollably and lose their ability to 
differentiate to functioning components of the blood (Sykes et al 
p. 989). 
AML has a 26.6% 5-year survival rate, and 5-10-month survival 
rate for patients who cannot tolerate the high intensity 
chemotherapy that is often required for complete remission (Cruz 
et al p. 53). Relapse rate is reported to be 30% to 40% within the 
first three years (Cruz et al p. 54). 
The disease process is multi-faceted, with many factors that are 
believed to cause AML, from genetics to environmental exposures 
(Wang & Bailey, 2016).
Illustration of differentiation of blood stem cells. Myeloid stem cells 
differentiate into many different specialized cells, such as red blood 
cells, platelets, and granulocytes. Figure from the National Cancer 
Institute (NIH, 2017).
Treatment 
The goal of treatment for AML, which can be either a combination of 
chemotherapy and/or radiation alone, or with a stem cell transplant, is 
complete remission. Partial remission has shown to have no benefit to survival 
(www.cancer.gov, 2017). 
Treatment is intensive to endure. Patients must first go through chemotherapy 
and/or radiation to achieve complete remission status, followed by another 
course of high intensity chemotherapy and/or radiation to prepare for 
hematopoietic stem cell transplantation (HSCT). Patients receive  stem cells 
from a donor (allogeneic or allo-HSCT) (Mosseso, p. 22). 
The goal of HSCT is to have engraftment of the donor cells, which will begin to 
produce healthy cells. Engraftment of neutrophils can take up to 20 days, and 
engraftment of platelets can take up to eight weeks (Mosseso, p. 25). The ANC, 
or absolute neutrophil count must be at least 500/mm3 for engraftment. 
Platelet count must be at least 20,000 platelets per microliter for platelet 
engraftment (Mosseso, p. 25).
Complications
AML patients who receive allo-HSCT have complications related to their body’s 
defense against the foreign cells (Mosseso, p. 23). Immunosuppressive drugs are 
given to prevent rejection, or patients may receive a combination of 
immunosuppressive drugs and T cell removal from donor cells (Mosseso, p. 24-25). 
Complications also arise from pancytopenia secondary to intensive chemotherapy 
regimens. Patients are at a high risk for infection and bleeding. They need blood 
transfusions and antibiotic coverage (WHO, 2014 p. 11). Of note, cardiotoxicity is a 
potential side effect of the chemotherapies daunorubicin and idarubicin. Central 
nervous system toxicity is a side effect of cytarabine. Patients can develop severe 
diarrhea and mucositis secondary to chemotherapy effects as well (WHO, 2014 p. 
11).
Graft versus host disease (GVHD) can be a severe chronic or acute process. T cells 
by the donor activate an immune response in the recipient, which results in an 
inflammatory response, causing GVHD. Getting the best possible match of major 
histocompatibility antigens is beneficial in curtailing GVHD (Sairafi et al, p. 1).
Lastly, patients suffer from an enormous amount of emotional and physical stress 
both during and after treatment. Patients report negative side effects, including 
both the emotional and financial burden of treatment, as well as long-term effects 
of treatment (Ghodraty-Jabloo et al, pp. 2037-2041) 
Genetic Discoveries
Genetic factors play an important role in 
both the diagnosis and the treatment of 
AML. It has been widely accepted that 
genetic mutations, specifically translocations, 
have an important impact on disease 
presentation and treatment (Ohgami & 
Arber, pp. 122-123).
The average AML genome contains 
approximately 400 mutations (Link, Wolff &
Wolff, p. 409).
Billions of dollars were spent to first map the 
human genome, something that can be done 
in four to six weeks now, at a cost of $10,000 
to $20,000 (Link, Wolff & Wolff, p. 410).
The first AML genome was mapped in 2008, 
and since then dozens of mutations have 
been discovered. (Link, Wolff & Wolff, p. 
410). Mutations discovered are not “driver” 
mutations, in that they do not cause the 
stem cells to start mutating. Rather they are 
“background” mutations, in that they can 
help predict outcomes and relapses (Link, 
Wolff & Wolff p. 409). 
Specific gene mutations, such as the RUNX1-
RUNXT1 (10-20% of cases), CBFB-MYH11 (5-
10% of cases), PML-RARA (10-20% of cases 
(Ohgami & Arber pp. 123-124).
Deletions and multiple translocations prove a 
poor prognosis (Ohgami & Arber p. 124).
The World Health Organization distinguishes 
AML by the genetic composition of AML. This 
guides providers to determine the most 
appropriate plan for patients (Wang & Bailey, 
p. 1215).
Treatment plans are tailored to the specific 
type of genetic mutations and abnormalities 
for improved outcomes  (Wang & Bailey, p. 
1215).
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